Anti-angiogenic agent

Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters... 

Nowak-Sliwinska, P., Ballini, J. P., Wagnieres, G. 8c van den Bergh, H. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc. Res. 79, 21-28 (2010). 

How to cite this article Nazarov, A. A. et al. Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters. Sci. Rep. 3, 1485 DOL10.1038/ srep01485 (2013). 

Sin N, Meng L, Wang MQW, Wen JJ, Bommann WG Crews CM. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94 6099-6103. 

Nusgens, B.V and Castronovo, V. (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21, 427-436. 

Teicher BA, Holden SA, AraG, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994 57 920-925. 

Kwon, H. J. (2003). Chemical genomics-based target identification and validation of anti-angiogenic agents. Current Medicinal Chemistry 10, 717-736. 

Isaacs JT, et al. (2006) Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 66(16) 1768-1778... 

Loweher, W. T., McMillen, D. A., Orville, A. M., Matthews, B. W. (1998). The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia call methionine aminopeptidase. Proc. Nat. Acad. ScL USA, 95, 12153-12157. 

Auricchio A, Behling K, O Connor E, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002 6 490-494. 

Based on the results described above, Eyetech received Food and Drug Administration approval to market pegaptanib sodium for treatment of patients with neovascu-lar AMD. This drug is the first anti-angiogenic agent to receive approval to treat AMD. 

MDM2 Inhibitors as Potential Anti-angiogenic Agents. 72... 

RGD peptides Tripeptide sequencer close to caspase-3 active site Disrupts intramolecular interaction resulting in caspase-3 activation Clinical use as antithorobic agent Potenteial use as anti-angiogenic agent 98... 

Other niches comprising reticular and endothelial cells known to secrete factors that promote self-renewal and survival have been found in close association with the vasculature [108]. Since the niche is dependent on the presence of an efficient blood supply, one therapeutic strategy would be to target the niche endothelium. Clinical use of anti-angiogenic agents has accelerated in... 

Segal, E., Satchi-Fainaro, R. Design and development of polymer conjugates as anti-angiogenic agents. Adv. Drug Deliv. Rev. 2009,61 (13), 1159-1176. 

---